سعر برونكولين إس 0.5% محلول تنفس 30 مل 2024

Salbutamol 0.5% (5 mg/ml) respirator solution 30 ml for nebulisation (EIPICO).

• Routine management of chronic bronchospasm unresponsive to conventional therapy, and treatment of acute severe asthma; adults, adolescents and children 4-11 years (UK Ventolin Respirator Solution SmPC). EIPICO page aligns with asthma/COPD bronchospasm indication.Population: As labelled / per sourceMHRA eMC, EIPICO

• Common: tremor, headache, tachycardia; uncommon: palpitations, mouth/throat irritation, muscle cramps; rare: hypokalaemia; very rare: hypersensitivity, paradoxical bronchospasm, arrhythmias; unknown: myocardial ischaemia, lactic acidosis (UK SmPC).International label, same formulation · MHRA eMC

• Hypersensitivity to salbutamol or excipients; non-IV salbutamol must not be used to arrest uncomplicated premature labour or threatened abortion (UK SmPC).International label, same formulation · MHRA eMC

• Inhalation only; monitor potassium in acute severe asthma; lactic acidosis with high nebulised doses; cardiovascular effects/myocardial ischaemia rare; paradoxical bronchospasm; contains benzalkonium chloride in UK product — check Egyptian excipients; seek care if becoming less effective (UK SmPC).International label, same formulation · MHRA eMC

• Non-selective beta-blockers (e.g. propranolol)Should not normally be prescribed with non-selective beta-blockers such as propranolol (UK SmPC).MHRA eMC

• Use in pregnancy only if expected benefit outweighs risk; probably secreted in breast milk — restrict nursing use when benefit outweighs neonatal risk (UK SmPC).International label, same formulation · MHRA eMC

• Salbutamol: Stimulates beta-2 adrenergic receptors in airway smooth muscle, increasing cyclic AMP and causing bronchodilation.